Redhill Biopharma
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 113
- Market Cap
- $9.6M
- Website
- http://www.redhillbio.com
- Introduction
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
- Conditions
- Covid19
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 61
- Registration Number
- NCT04723537
- Locations
- 🇺🇸
Beautiful Minds Clinical Research, Cutler Bay, Florida, United States
🇺🇸Research in Miami Inc., Hialeah, Florida, United States
🇺🇸South Florida Research Phase I-IV, Inc., Miami Springs, Florida, United States
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
- Conditions
- Pulmonary Mycobacterium Avium Complex InfectionBronchiectasisLung Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 12
- Registration Number
- NCT04616924
- Locations
- 🇺🇸
Medical Facility, Wauwatosa, Wisconsin, United States
🇺🇸Medical Facility 1, Orlando, Florida, United States
🇺🇸Medical Facility 2, Orlando, Florida, United States
Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- RedHill Biopharma Limited
- Registration Number
- NCT04502069
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 475
- Registration Number
- NCT04467840
- Locations
- 🇺🇸
ABC-201 Site 901, Detroit, Michigan, United States
🇧🇷ABC-201 Site 408, Belo Horizonte, Brazil
🇧🇷ABC-201 Site 411, Belo Horizonte, Brazil
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 42
- Registration Number
- NCT04414618
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
- Conditions
- Traveler's Diarrhea
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 142
- Registration Number
- NCT04027894
Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
- Conditions
- Traveler's Diarrhea
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 142
- Registration Number
- NCT04026984
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
- Conditions
- CholangiocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma, PerihilarCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, Intrahepatic
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- RedHill Biopharma Limited
- Registration Number
- NCT03414489
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticCholangiocarcinoma Non-resectableCholangiocarcinoma, PerihilarCholangiocarcinoma
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 65
- Registration Number
- NCT03377179
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
- Conditions
- Helicobacter Pylori InfectionDyspepsia
- Interventions
- Drug: Active Comparator
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 455
- Registration Number
- NCT03198507
- Locations
- 🇺🇸
Research Site, Lynchburg, Virginia, United States
🇺🇸Research site, Milwaukee, Wisconsin, United States
🇺🇸Research Center, Houston, Texas, United States